Company / Net Income
Ultragenyx Pharmaceutical Inc. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$575.0M
FY2025
5-year range
-$707.4M / -$402.7M
FY2021-FY2025
Trend
-1.1%
vs FY2024
Sector context
#200 of 216
Health Care
What the data says
Among 216 Health Care companies, Ultragenyx Pharmaceutical Inc. is in the bottom 7% for net income. Net Income has fluctuated over the past 10 years, ranging from -$707M in FY2022 to -$60M in FY2016.
Based on SEC 10-K filings.
-$575M in FY2025.
Improved from -$607M to -$575M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 216This company -$575.0M Sector average $454.3M
▼
-226.6% below sector average
Key checks
Key Insights
- In FY2025, net income decreased 1.1% year-over-year.
- Ranks #200 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2016.
- Lowest net income in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$575.0M | -1.1% |
| FY2024 | -$569.0M | +6.3% |
| FY2023 | -$607.0M | +14.2% |
| FY2022 | -$707.4M | -75.7% |
| FY2021 | -$402.7M | -103.8% |
| FY2020 | -$197.6M | +34.6% |
| FY2019 | -$302.1M | -52.9% |
| FY2018 | -$197.6M | -35.7% |
| FY2017 | -$145.6M | -143.5% |
| FY2016 | -$59.8M | +58.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026